



Announcement Summary

Entity name

CLARITY PHARMACEUTICALS LTD

Date of this announcement

Monday December 08, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
CU6AAM	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	34,655	01/12/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

CLARITY PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

143005341

1.3 ASX issuer code

CU6

1.4 The announcement is

New announcement

1.5 Date of this announcement

8/12/2025



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

1/12/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Options vest as follows, subject to the option holder remaining employed by the company:

25% on 1 December 2026

25% on 1 December 2027

50% on 1 December 2028

Issue details

Number of +securities

34,655

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CU6 : ORDINARY FULLY PAID	372,030,071

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	20,583,522
CU6AN : OPTION EXPIRING 10-MAY-2026 EX \$0.94	1,175,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13